ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

Rhea-AI Summary

ORIC Pharmaceuticals (Nasdaq: ORIC) will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC).

The company will present results on a conference call and webcast on March 31, 2026 at 4:30pm ET; a replay will be available for 90 days.

News Market Reaction – ORIC

-2.58%

1 alert

-2.58% News Effect

On the day this news was published, ORIC declined 2.58%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference call time: 4:30 pm ET Webcast replay period: 90 days ATM capacity: $200.0 million +5 more

8 metrics

Conference call time 4:30 pm ET Phase 1b rinzimetostat dose optimization data call on March 31, 2026

Webcast replay period 90 days Replay availability after March 31, 2026 presentation

ATM capacity $200.0 million Maximum common stock sales under renewed at-the-market program (2026 prospectus)

Prior ATM proceeds $139.7 million Gross proceeds from 13,478,432 shares sold under 2024 prospectus supplement

Shares sold via ATM 13,478,432 shares Total shares previously sold under Jefferies sales agreement

Shares outstanding 98,528,949 shares Common shares outstanding as of December 31, 2025

R&D expenses 2025 $109.8 million Research and development expenses for 2025 per Form 10-K

Cash and investments $392.3 million Cash, cash equivalents and investments as of December 31, 2025

Market Reality Check

Price: $12.06 Vol: Volume 1,737,547 vs 20-da...

normal vol

$12.06 Last Close

Volume Volume 1,737,547 vs 20-day average 1,593,344 (relative volume 1.09x). normal

Technical Trading above 200-day MA of 11.01 with current price at 12.38, about 17% below 52-week high 14.93.

Peers on Argus

ORIC gained 5.81% while peers like ELVN (+10.21%), NUVB (+3.76%) and others also...

ORIC gained 5.81% while peers like ELVN (+10.21%), NUVB (+3.76%) and others also traded higher, but no peers appeared in the momentum scanner and no same-day peer headlines were flagged, suggesting a stock-specific move.

Historical Context

5 past events · Latest: Mar 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 17	Preclinical data posters	Positive	-10.0%	AACR acceptance of multiple preclinical rinzimetostat posters in prostate cancer models.
Mar 06	Inducement equity grants	Neutral	-15.0%	Inducement stock options and RSUs granted to a new non-executive employee.
Feb 23	Earnings and pipeline	Positive	+14.6%	Q4 and 2025 results plus Phase 1b data and strong cash runway into 2H 2028.
Feb 06	Inducement equity grants	Neutral	+2.8%	Inducement stock options and RSUs to three new non-executive employees.
Feb 05	Investor conferences	Neutral	+4.6%	Participation in three February investor conferences with webcasts and replays.

Pattern Detected

Most prior news events (4 of 5) saw price moves that aligned with the news tone, with one notable selloff after seemingly positive Rinzimetostat AACR data.

Recent Company History

Over recent months, ORIC has highlighted steady progress across clinical and corporate fronts. On Feb 23, 2026, it reported Q4 and 2025 results, emphasizing Phase 1b data for rinzimetostat and enozertinib plus a strong cash position of $392.3M, which coincided with a 14.6% gain. Routine inducement grant announcements in February and March saw modest or negative moves. Preclinical Rinzimetostat AACR posters on Mar 17 preceded a 10.02% decline, showing the stock can sell off even on ostensibly positive scientific updates.

Market Pulse Summary

This announcement flags an upcoming Phase 1b combination dose optimization readout for rinzimetostat...

Analysis

This announcement flags an upcoming Phase 1b combination dose optimization readout for rinzimetostat in mCRPC, with a conference call set for 4:30 pm ET on March 31, 2026 and a 90-day webcast replay. It builds on earlier clinical and preclinical disclosures around the same asset. In parallel, ORIC maintains sizable cash resources of $392.3M and an expanded ATM program, so investors may watch both data quality and any future use of equity financing.

Key Terms

phase 1b, metastatic castration resistant prostate cancer, mCRPC

3 terms

phase 1b medical

"report combination dose optimization data from the Phase 1b trial of rinzimetostat"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

metastatic castration resistant prostate cancer medical

"Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer"

An advanced form of prostate cancer that has spread beyond the prostate to other parts of the body and continues to grow despite treatments that lower male hormones (often called androgen-deprivation therapy). Investors care because it defines a high unmet medical need and a clear market for new drugs, diagnostics, and therapies; treatment breakthroughs, trial results, or regulatory approvals can materially affect sales potential and company valuations, much like unlocking a new market for a stubborn problem.

mCRPC medical

"rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC)"

mCRPC stands for metastatic castration‑resistant prostate cancer, a form of prostate cancer that has spread beyond the prostate and keeps progressing despite treatments that lower male hormones. It matters to investors because this stage is harder to treat, drives demand for new therapies, and often involves large, expensive clinical trials and regulatory decisions that can strongly influence a drug maker’s future revenue and stock value—think of it as a stubborn problem that creates both medical need and commercial opportunity.

AI-generated analysis. Not financial advice.

Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Tuesday, March 31, 2026 at 4:30pm ET.

To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor targeting EGFR exon 20 and EGFR PACC mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

When will ORIC (ORIC) present the Phase 1b rinzimetostat combination dose optimization data?

ORIC will present the dose optimization data on March 31, 2026 at 4:30pm ET. According to the company, the data will be discussed on a live conference call and webcast with a live Q&A session for investors.

How can investors access ORIC's March 31, 2026 webcast for rinzimetostat (ORIC-944) data?

Investors can access the webcast via the company's investor website and by telephone with preregistration. According to the company, preregistration provides a dial-in number and unique passcode for the live call and Q&A.

What data will ORIC (ORIC) report for rinzimetostat in mCRPC on March 31, 2026?

The company will report combination dose optimization data from the Phase 1b trial in mCRPC patients. According to the company, the presentation focuses on dose optimization findings for rinzimetostat (ORIC-944) in that population.

Will ORIC's March 31, 2026 webcast of rinzimetostat results be available for replay?

Yes, the live webcast will be available for replay for 90 days after the presentation. According to the company, an audio archive and webcast replay will be posted in the investor section of its website.

Does ORIC (ORIC) offer a live Q&A during the March 31, 2026 rinzimetostat presentation?

Yes, a live Q&A session will be offered during the conference call and webcast. According to the company, phone participants must preregister to receive the telephone number and unique passcode to join the session.

What is the focus of ORIC's Phase 1b trial update for rinzimetostat (ORIC-944) in mCRPC?

The update focuses on combination dose optimization data in metastatic castration resistant prostate cancer patients. According to the company, the results will inform dosing strategy for further clinical development.